02098nas a2200205   4500008004100000024000700041245018600048210006900234260001700303300001200320490000700332520139800339653000901737653000901746653002001755100002201775700002601797700002901823856004001852       2022                        eng d  a3000aVancomycin, Linezolid, and Ceftaroline In vitro Activity Against Methicillin susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA) Isolates0 aVancomycin Linezolid and Ceftaroline In vitro Activity Against M  cOctober 2022  a671-6740 v143 a<p class="rtejustify">MRSA-infected patients incur twice as many costs as MSSA-infected patients. Vancomycin, Linezolid, and, most recently, Ceftaroline are among Indonesia's several MRSA treatment options. Therefore, we sought to assess the efficacy of these three medications. The investigation was done at the Dr. Soetomo General Academy Hospital's Clinical Microbiology Laboratory in Surabaya. The bacterium ATCC 25923, ATCC 43300, MSSA clinical isolate, and MRSA clinical isolate of <em>Staphylococcus aureus</em> were studied. Vancomycin, Linezolid, and ceftaroline were administered at respective dosages of 1 MIC, 2 MIC, and 4 MIC. In addition, a time-kill test was performed, which consisted of counting the growth of colonies on solid media, generating a time-kill curve, and determining MBC. The number of colonies in the antibiotic groups at 4, 6, and 8 hours varied significantly, according to the study (Vancomycin, Linezolid, and Ceftaroline). In contrast, the number of bacteria did not differ significantly between Vancomycin and Linezolid until the fourth hour. Except at 6 and 24 hours, neither Vancomycin nor Ceftaroline significantly altered the number of bacteria. There was a significant difference in the number of colonies between Ceftaroline and Linezolid at 4, 6, and 8 hours. Vancomycin, Linezolid, and Ceftaroline against MSSA and MRSA isolates vary greatly.</p>
10aMRSA10aMSSA10aTime-kill curve1 aPurwoningsih, Eny1 aEndraswari, Pepy, Dwi1 aWidodo, Agung, Dwi Wahyu  uhttps://www.phcogj.com/article/1887